Answers are grounded in this paper and cite their sources.
Investigates interactions within the ULK1 complex in cancer cells, suggesting new therapeutic avenues.
(Macro-)Autophagy is a major intracellular recycling pathway mediating the removal of longlived or damaged proteins or organelles. Autophagy occurs at basal levels in most cell types and ensures cellular homeostasis. Additionally, autophagy is actively induced under stress conditions such as nutrient or growth factor deprivation, hypoxia, treatment with chemotherapeutics, protein aggregation, or infection with intracellular pathogens. The dysregulation of autophagy is associated with various diseases, including cancer, infectious diseases and neurodegenerative diseases. In cancer, autophagy plays a rather ambivalent role, depending on the stage and type of cancer. Accordingly, both tumor-suppressing and -promoting activities of autophagy have been described. In recent years, the molecular machinery controlling this process has been identified and characterized. The ULK1 complex, consisting of the Ser/Thr kinase ULK1 and the associated proteins ATG13, ATG101 and FIP200/RB1CC1, represents a central element for the induction of autophagy. In previous DFG-funded projects, we were able to characterize the protein-protein interactions (PPIs) within the ULK1 complex. With this proposal, we aimed to utilize this knowledge and develop small molecules or peptidomimetics that interfere with PPIs of the ULK1 complex. In addition, the identified inhibitors should be tested for their autophagy-inhibiting/modulating potential and for their efficacy in preclinical model systems. Using both an in vitro high-throughput and a virtual structure-based screening approach, we identified four small molecules (AFS30, AFS32, KMG24, KMG28) that interfere with the ATG13-ATG101 interaction within the ULK1 complex. We were able to show that these four compounds inhibit the cellular ATG13-ATG101 interaction and significantly reduce autophagic activity. The two AFS compounds preferentially bind to ATG13 and interfere with the interaction allosterically, whereas the two KMG compounds preferentially associate with ATG101 and act via an orthosteric mode of action. Additionally, AFS30 and AFS32 sensitize nutrient-restricted cancer cells to apoptosis. All compounds exhibit suitable physicochemical properties that support their further development as therapeutic agents. Therefore, we propose that these validated hits represent a promising step for the further development of autophagy inhibitors targeting the ATG13-ATG101 heterodimer.
No takes yet. Share an insight, caveat, or question.
Stork et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: